Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880475 | 0.82 | DPP4 (0.36) | DPP4 | |
| SCHEMBL19879498 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL19779544 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL25854984 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL19879501 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL19768960 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL9004988 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL19768934 | 0.81 | OPRK1 (0.30) | DPP4 | |
| SCHEMBL21451672 | 0.78 | — | — | |
| SCHEMBL24800361 | 0.77 | DPP4 (0.44) | DPP4HRH3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | DPP4 1963/4885HRH3 1000/4885DRD2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.